GlassScriptPhysician profile
Anna O Ehret
NPI 1013057017
$1,429.66
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $305 · 2021: $116 · 2022: $113.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $553.79 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $258.55 | 2019-2020 | |
| Ptc Therapeutics, INC. | $160.11 | 2019 | |
| Greenwich Biosciences, INC. | $145.88 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $112.90 | 2022 | |
| Neurelis, INC. | $92.57 | 2021 | |
| Eisai INC. | $40.82 | 2019 | |
| Ucb, INC. | $33.72 | 2019-2020 | |
| Sarepta Therapeutics, INC. | $18.42 | 2020 | |
| Livanova USA, INC. | $12.90 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Ehret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.